الفهرس يوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 376 |  |  |
| | | from | 376 | | |
المستخلص
Out of 591 samples (35 human samples, 115 egg samples, 111 organ samples, 184 swabs, 100 environmental samples and 46 other types of samples) The prevalence of klebsiella isolates were (54.3%, 23.5%,16.2% , 11.4%, 36% and 8.7%) in them respectively. Klebsiella isolates recovered from (human, eggs, organs, swabs, environment, other sources) recorded strong biofilm producers in a percentage of 21.1%, 11.1%, 11.1% 14.3%, 19.4% and 0%) while recorded moderate biofilm producers in a percentage of 31.6%, 48.1%, 50%, 38.1%, 36.1% and 75%). The drugs of choice for treatment of Klebsiella infections are ciprofloxacin, Nalidixic acid and Imipenem. XDR, MDR and PDR isolates were 50.4%, 40% and 5.6% respectively.72.8% of klebsiella isolates were recorded as non ESBL producers, 15.2% of them were ESBL producer, 7.2% of them were class D OXA , 3.2% of them were class B Ý metallo beta lactamase NDM1, 2.4% of them were AmpC producer and 1.6% of them were class A KPC producer. Overall ESBL producing klebsiella isolates showed resistance to antibiotics higher than non ESBL producing klebsiella isolates. All biofilm producers Klebsiella isolates were showed high resistance to aztreonam, cefepime, cefoxitin amoxicillin-clavulnic and ciprofloxacin than non biofilm producers. Virulence genes (gyr A and 16srRNA) were detected in 100% of the tested isolates so all examined isolates recorded as klebsiella pneumoniae. (K1, rmpA and aerobactin) genes were detected in a percentage (2.3%, 27.3% and 10.2%) of the tested klebsiella pneumoniae. K2 gene was not detected in the tested klebsiella pneumoniae